Genital tract viral load in HIV type 1-positive women correlates with specific cytokine levels in cervical-vaginal secretions but is not a determinant of infectious virus or anti-HIV activity

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1533-1539

  Mukura, Lucy R ^a   Ghosh, Mimi ^a,c   Fahey, John V ^a   Cu Uvin, Susan ^b   Wira, Charles R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; CYTOKINE; ELAFIN; EOTAXIN; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ASSAY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TISSUE LEVEL; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF DETECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; VAGINAL LAVAGE; VAGINAL SECRETION; VAGINITIS; VIRUS INFECTIVITY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; CERVIX UTERI; CYTOKINES; FEMALE; HIV-1; HUMANS; MIDDLE AGED; RNA, VIRAL; VAGINA; VAGINAL DOUCHING; VIRAL LOAD;

EID: 84868516469     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0394     Document Type: Article

References (56)

1. WHO, Women and Health: Today's evidence tomorrow's agenda. http://whqlibdoc.who.int/publications/2009/9789241563857-eng.pdf, 2009.
2. Baeten JM, et al.: Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Translational Med 2011;3(77):77ra29.
3. Mofenson LM, et al.: Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341(6):385-393.
4. Anderson BL, et al.: Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis 2008;47(9):1216-1221.
5. Cu-Uvin S: Association between paired plasma and cervi-covaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006;42(5):584-587.
6. McClelland RS, et al.: Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002;16(18):2425-2430.
7. Heffron R, et al.: Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2011(11): http://dx.doi.org/10.1016/S1473-3099(11) 70247-X.
8. Clemetson DB, et al.: Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA 1993;269(22):2860-2864.
9. Kovacs A, et al.: Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358(9293):1593-1601.
10. Vernazza PL, et al.: Quantification of HIV in semen: Correlation with antiviral treatment and immune status. AIDS 1997;11(8):987-993.
11. Speck CE, et al.: Risk factors for HIV-1 shedding in semen. Am J Epidemiol 1999;150:622-631.
12. Mostad SB: Prevalence and correlates of HIV type 1 shedding in the female genital tract. AIDS Res Hum Retroviruses 1998;14:S11-S15.
13. Kaul R, et al.: The genital tract immune milieu: An important determinant of HIV susceptibility and secondary transmission. J Reproduct Immunol 2008;77(1):32-40.
14. Cu-Uvin S, et al.: Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010;24(16):2489-2497.
15. Ghosh M, et al.: Anti-HIV activity in cervical-vaginal secretions from HIV-positive and-negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS ONE 2010;5(6):e11366.
16. Royce RA, et al.: Sexual transmission of HIV. N Engl J Med 1997;336(15):1072-1078.
17. Ghosh M, et al.: Trappin-2/Elafin: A novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 2010;129(2):207-219.
18. Gray RH, et al.: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357(9263):1149-1153.
19. Wawer MJ, et al.: Rates of HIV-1 transmission per coital act, by stage of HIV-1 Infection, in Rakai, Uganda. J Infect Dis 2005;191(9):1403-1409.
20. Wira CR, et al.: Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus. Mucosal Immunol 2011;4(3):335-342.
21. Fahey JV, et al.: Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture. Mucosal Immunol 2008;1(4):317-325.
22. Ghosh M, et al.: CCL20/MIP3a is a novel anti-HIV-1 molecule of the human female reproductive tract. Am J Re-product Immunol 2009;62(1):60-71.
23. Shine NR, et al.: Secretory leukocyte protease inhibitor: Inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein. Bioorg Chem 2002;30(4):249-263.
24. Novak RM, et al.: Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin. Vaccine Immunol 2007;14(9):1102-1107.
25. Iqbal SM, et al.: Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009;23(13):1669- 1677.
26. Amsel R, et al.: Nonspecific vaginitis: Diagnostic criteria and epidemiologic associations. Am J Med 1983;74:14-22.
27. Wei X, et al.: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46(6):1896-1905.
28. Klotman ME and Chang TL: Defensins in innate antiviral immunity. Nat Rev Immunol 2006;6(6):447-456.
29. Wira CR, et al.: Innate immunity in the human female reproductive tract: Endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 2011;65(3):196-211.
30. Venkataraman N, et al.: cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005;175(11):7560-7567.
31. Cummins JE Jr, et al.: Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method. J Clin Microbiol 2003;41(9):4081-4088.
32. Cummins JE, et al.: Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 2006;22(8):788-795.
33. Kovacs A, et al.: HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1. J Acquir Immune Defic Syndr 1999;22(2):124-131.
34. Cohn JA, et al.: HIV-inducing factor in cervicovaginal secretions is associated with bacterial vaginosis in HIV-1-infected women. J Acquir Immune Defic Syndr 2005;39(3):340-346.
35. Olinger GG, et al.: Association of indicators of bacterial va-ginosis with a female genital tract factor that induces expression of HIV-1. AIDS 1999;13(14):1905-1912.
36. Shebl FM, et al.: Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retroviruses 2011. (Epub ahead of print); DOI:10.1089/aid.2011.0144.
37. Combadière B, et al.: The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS 2003; 17(9):1279-1290.
38. Capobianchi MR, et al.: Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res Hum Retroviruses 1998;14(3):233-240.
39. Cocchi F, et al.: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8 + T cells. Science 1995;270(5243):1811-1815.
40. Iqbal SM, et al.: Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 2005;192(5):728-738.
41. Asin SN, et al.: HIV type 1 infection in women: Increased transcription of HIV type 1 in ectocervical tissue explants. J Infect Dis 2009;200(6):965-972.
42. Gregory T, et al.: Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses 2008;24(7):973-976.
43. Poli G, et al.: Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcrip-tional and post-transcriptional mechanisms. J Exp Med 1990;172(1):151-158.
44. Poli G and Fauci AS: Cytokine modulation of HIV expression. Sem Immunol 1993;5(3):165-173.
45. Zara F, et al.: Markers of local immunity in cervico-vaginal secretions of HIV infected women: Implications for HIV shedding. Sex Transm Infect 2004;80(2):108-112.
46. Osborn L, Kunkel S, and Nabel GJ: Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989;86(7):2336-2340.
47. Mitchell C, et al.: Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses 2011;27(1):35-39.
48. Fahey JV, et al.: New approaches to making the microenvironment of the female reproductive tract hostile to HIV. Am J Reprod Immunol 2011;65(3):334-343.
49. Moreau T, et al.: Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008;90(2):284-295.
50. Shaw JL and Diamandis EP: A potential role for tissue kal-likrein-related peptidases in human cervico-vaginal physiology. Biol Chem 2008;389(6):681-688.
51. Shaw JLV., et al.: Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. Biol Chem 2008;389(12):1513-1522.
52. Yamasaki K, et al.: Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006;20(12):2068-2080.
53. Keller MJ, et al.: PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007;21(4):467-476.
54. Al-Harthi L, et al.: Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J Acquir Immune Defic Syndr 1999;21(3):194-202.
55. Cu-Uvin S, et al.: Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis 2001;33(6):894-896.
56. Taha TE, et al.: HIV infection and disturbances of vaginal flora during pregnancy. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(1):52-59.